Main Content

Stanley V. Smith, PhD

Professor of Pharmacology and Toxicology, School of Medicine
Director, Mass Spectrometry Core Facility (MSCF)

Director, Medical Pharmacology (PH620)

Director, Dental Pharmacology (DENT626)

Director, Fundamental Pharmacology (PHARM726)

Office: R420
Lab: R416; R417; G477
(601) 815-1268

Research interests

  • Understanding disease models and mechanisms (hypertension, cardiovascular, obesity, diabetes and kidney disease)
  • Characterization of biomarkers in human illness/disease
  • Understanding and preventing adverse drug responses (ADRs)
  • Disparities in health and treatment outcomes
  • Pharmacokinetics/pharmacodynamics/drug metabolism
  • Alcohol/drug-induced hepatotoxicity mechanisms
  • Proteomics/peptidomics/lipidomics/metabolomics
  • Mass spectrometry: methods, data collection and analysis
  • UMMC Mass Spectrometry Core Facility (MSCF)

Current research

My research interests are in understanding the dynamic interplay between protein structure and conformation and how this is manifested in protein function. Cytochrome P450s became my research focus while at the National Cancer Institute and this interest continues to this day. I previously used laser flash photolysis and other biophysical techniques to investigate conformational dynamics of these hemeproteins in order to explain their unique substrate and inhibitor binding properties. These factors govern, among other things, how the P450s in the liver are involved in drug and xenobiotic metabolism and how the P450s cause adverse events resulting in therapeutic failures, hepatotoxicity, and other disruptions of liver function as well as morbidity and mortality. 

I am also interested in the lipid signaling mediators generated by cytochrome P450s and their roles in hypertension, kidney disease, and other human illnesses. I want to understand their involvement in disparate health outcomes of African Americans with chronic kidney disease and am participating in a research collaboration to investigate this. The goal of that collaboration is to investigate the mechanisms underlying the disparate health outcomes of African Americans with chronic kidney disease compared to Caucasians. In addition, the mechanisms underlying the roles of other risk factors such as hypertension and diabetes in the development of kidney disease will be investigated.

In addition, I am investigating the roles angiotensin II and its metabolites play in hypertension. Specifically, I have developed LC/MS/MS methods to quantify pg levels of angiotensin II and other angiotensin metabolites in plasma, tissue, and other biological materials. I have extensive training in protein biochemistry (HPLC, LC/MS/MS, Cysteine/Disulphide chemistry and reactivity, protein folding, protein purification), pharmacology (Pharmacokinetic/Pharmacodynamics, Diabetes/Hypertension/Cardiovascular), and Proteomics/Lipidomics/Metabolomics techniques. I will use these skills and others to continue to focus on research projects, collaborations, and other endeavors that will help understand the mechanisms of and offer new approaches to treating human illness and disease. 

I am especially in understanding diseases where there are disparate health outcomes and that are amenable to translational research. I plan to also continue outreach efforts aimed at ensuring that awareness, science and health education, and information is disseminated to students, educators, and researchers throughout the state via outreach efforts facilitated by my long-standing involvement with the Mississippi Academy of Sciences as well as other minority outreach organizations with which I am involved.

Selected publications

  • Lindsey ML, Gomes AY, Smith SV, de Castro Bras LE. How to Design a Cardiovascular Proteomics Experiment, p. 33-57. In: Agnetti G, Lindsey ML, and Foster DB, editors. Manual of Cardiovascular Proteomics. New York: Springer Berlin Heidelberg; 2016 (ISBN 978-3-319-31828-4). 
  • Poole, A.R., Enwerem, I.I., Vicino, I.A., Coole, J.B., Smith, S.V., and Hebert, M.D. (2016). Identification of processing elements and interactors implicate SMN, coilin and the pseudogene-encoded coilp1 in telomerase and box C/D scaRNP biogenesis, RNA Biology, manuscript accepted for publication.
  • Kyle, P.B., Smith, S.V., Baker, R.C. and Kramer, R.E. (2012). Mass spectrometric detection of CYP450 adducts following oxidative desulfuration of methyl parathion, J. Applied Toxicol Jan 23. doi: 10.1002/jat.1792. PMID: 22271348 [Epub ahead of print]
  • Dreisbach, A.W., Smith, S.V., Kyle, P.B., Ramaiah, M., Amenuke, M., Garrett, M.J., Lirette, S.T., Griswold, M.E., and Roman, R.J. (2014). Urinary CYP Eicosanoid Excretion Correlates with Glomerular Filtration in African-Americans with Chronic Kidney Disease, Prostaglandins Other Lipid Mediat. Prostaglandins Other Lipid Mediat., Aug 21. pii: S1098-8823(14)00033-1. doi: 10.1016/j.prostaglandins.2014.08.002. [Epub ahead of print] PMID: 25151892 [PubMed - as supplied by publisher]
  • Fan, F., Geurts, A.M., Pabbidi, M.R., Smith, S.V., Harder, D.R., Jacob, H., and Roman, R.J. (2014).  Zinc-finger nuclease knockout of dual-specificity protein phosphatase-5 enhances the myogenic response and autoregulation of cerebral blood flow in FHH.1.BN rats., PLoS One, 9(11):e112878